Histrelin
Hormonal / ClinicalAlso known as: Vantas, Supprelin LA
Mechanism
A GnRH agonist delivered as a tiny implant placed under the skin of the arm that lasts a full 12 months — the longest-acting GnRH formulation available. One simple office procedure per year replaces daily or monthly injections. Used for prostate cancer (Vantas) and central precocious puberty in children (Supprelin LA), where consistent hormone suppression is critical.
Technical detail
Synthetic GnRH agonist nonapeptide — [D-His(Bzl)6, Pro9-NHEt]-GnRH. D-His(benzyl) substitution at position 6 provides ~100x greater potency than native GnRH. Delivered via hydrogel (poly-2-hydroxyethyl methacrylate) subcutaneous implant (3cm x 3.5mm cylinder) placed in inner upper arm under local anesthesia. Implant matrix provides controlled diffusion-based release of histrelin at ~65 mcg/day (Vantas, 50mg) or ~65 mcg/day (Supprelin LA, 50mg) for 12 months. Steady-state suppression achieved by month 1. Testosterone suppressed to castrate levels (<50 ng/dL in >95% of prostate cancer patients). In central precocious puberty: suppresses LH to prepubertal levels, halts pubertal progression, and allows catch-up in predicted adult height. Implant removed/replaced at 12 months — can leave small scar. Advantage over depot injections: truly continuous release (no end-of-dose escape), one procedure per year, palpable for confirmation of placement.
Effects
ENDOCRINE SYSTEM (REPRODUCTIVE AXIS): Histrelin is a superagonist GnRH analog (9 amino acids, substitution at position 6: D-His(Bzl) replaces Gly) delivered via a subcutaneous hydrogel implant providing continuous release for 12 months [RCT, FDA-approved]. Initial phase: transient GnRH receptor stimulation causing an LH/FSH surge ("flare") lasting 2-4 weeks — testosterone rises transiently in prostate cancer patients, estrogen rises in precocious puberty patients [RCT, clinical]. Chronic phase: continuous GnRH receptor exposure causes receptor downregulation and desensitization, resulting in profound suppression of LH, FSH, and downstream sex steroids [RCT]. In prostate cancer (Vantas): achieves castrate testosterone levels (<50 ng/dL, often <20 ng/dL) by week 4, maintained for 12 months — comparable to leuprolide and goserelin depot formulations [RCT — Schlegel, 2006]. In central precocious puberty (Supprelin LA): suppresses LH, FSH, estradiol/testosterone to prepubertal levels, halting premature sexual development and skeletal maturation [RCT — Eugster et al., 2007]. MUSCULOSKELETAL: In precocious puberty, halts premature epiphyseal fusion, preserving adult height potential — bone age advancement slows or pauses during treatment [RCT, long-term follow-up]. In prostate cancer, chronic testosterone suppression causes progressive bone density loss (1-4% per year at lumbar spine) — osteoporosis risk increases with treatment duration [clinical, systematic reviews]. METABOLIC: Androgen deprivation causes metabolic syndrome features — increased visceral fat, insulin resistance, dyslipidemia, elevated HbA1c [clinical, meta-analyses]. CARDIOVASCULAR: Emerging data suggests GnRH agonists may increase cardiovascular risk compared to GnRH antagonists — the mechanism may involve T-cell activation via extra-pituitary GnRH receptors on lymphocytes, promoting atherosclerotic plaque instability [observational, mechanistic studies]. NEUROPSYCHIATRIC: Testosterone suppression associated with cognitive changes (impaired visuospatial function), fatigue, depression, and hot flashes in prostate cancer patients [clinical]. HYDROGEL TECHNOLOGY: The histrelin implant uses a proprietary hydrogel diffusion-controlled reservoir — histrelin acetate is embedded within a non-biodegradable cylindrical hydrogel rod (3 cm x 3 mm), providing zero-order release kinetics for 12 months [pharmacokinetic, device engineering].
Practitioner Guide
ADMINISTRATION: Subcutaneous implant placed in the inner upper arm under local anesthesia. Vantas (prostate cancer): 50 mg histrelin, replaced every 12 months. Supprelin LA (precocious puberty): 50 mg histrelin, labeled for 12 months but clinical data supports efficacy up to 24 months in some patients (off-label extended use). IMPLANT PROCEDURE: Small incision (~1 cm), implant inserted with trocar into subcutaneous tissue, closed with Steri-Strips or single suture. Takes 15-20 minutes. Removal requires a second small incision at the implant site — localize by palpation or ultrasound if not palpable. Removal can be challenging if fibrous capsule has formed (more common after >12 months). FLARE MANAGEMENT (PROSTATE CANCER): The initial testosterone flare can cause disease progression (bone pain, urinary obstruction, spinal cord compression) in patients with advanced prostate cancer. Mitigate with: antiandrogen cover (bicalutamide 50 mg/day starting 1 week before implant and continuing 2-4 weeks after). Alternatively, consider relugolix (oral GnRH antagonist) which has no flare. MONITORING: Prostate cancer: PSA and testosterone at 1 month (confirm castration), then every 3-6 months. Testosterone should be <50 ng/dL (ideally <20 ng/dL). If testosterone escapes suppression before 12 months, replace implant early. Precocious puberty: LH, FSH, estradiol/testosterone at 1 month, then every 6 months. Monitor growth velocity, bone age annually. BONE PROTECTION (PROSTATE CANCER): Start denosumab 60 mg SC q6months or zoledronic acid 4 mg IV annually if treatment duration >12 months. Calcium 1200 mg/day + vitamin D 1000-2000 IU/day. DEXA scan at baseline and annually. Weight-bearing exercise prescription. ADVANTAGES OVER DEPOT INJECTIONS: Annual procedure vs. monthly/quarterly injections. More consistent drug levels (no peak-trough fluctuations). Better patient satisfaction for long-term therapy. No injection site reactions. DISADVANTAGES: Requires minor surgical procedure for insertion and removal. Risk of implant migration, breakage during removal, local infection. Not suitable for patients who cannot undergo the procedure. COST: Expensive — approximately $4,500-6,500 per implant plus procedure costs. Insurance typically covers for approved indications. STORAGE: Room temperature (25°C). Protect from light. Each implant is packaged in a sterile kit with insertion tool.
Research Summary
TIER 1: Pivotal RCTs for Vantas — Schlegel 2006: histrelin implant achieved castrate testosterone in 96% of prostate cancer patients at 52 weeks, non-inferior to leuprolide depot. Pivotal RCTs for Supprelin LA — Eugster et al., 2007: effective LH suppression in central precocious puberty maintained for 12 months. Long-term extension studies showing efficacy maintained with annual replacement for up to 5+ years. FDA-approved: Vantas (2004) for advanced prostate cancer, Supprelin LA (2007) for central precocious puberty. TIER 2: Systematic reviews of GnRH agonists for prostate cancer confirming class equivalence (histrelin, leuprolide, goserelin — similar efficacy). Meta-analyses of bone density loss with androgen deprivation therapy. Reviews of hydrogel implant technology and drug delivery engineering. Comparative reviews of GnRH agonists vs. antagonists for cardiovascular safety. Studies of extended Supprelin LA use beyond 12 months (up to 24 months in some pediatric centers). TIER 3: Pediatric endocrinology case series documenting real-world Supprelin LA outcomes including height preservation. Urology practice reports on implant insertion/removal techniques and complications (fibrous encapsulation, broken implants). International registry data on GnRH agonist use in prostate cancer. KEY FINDINGS: Histrelin implant offers genuine convenience — annual dosing is a meaningful advantage for patients requiring long-term GnRH suppression. Efficacy is equivalent to other GnRH agonist depot formulations. The hydrogel technology provides remarkably consistent drug release. Main limitations are the procedure requirement and cost. The emerging cardiovascular safety concern with GnRH agonists vs. antagonists may shift prescribing patterns toward relugolix. GAPS: No head-to-head RCTs of histrelin implant vs. relugolix. Long-term cardiovascular outcomes not specifically studied for histrelin. Optimal duration of extended Supprelin LA use in precocious puberty not established. ACTIVE TRIALS: Studies comparing GnRH agonists vs. antagonists for cardiovascular endpoints. Pediatric long-term outcome studies for Supprelin LA-treated precocious puberty patients.